Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lemborexant in Delayed Sleep Phase Syndrome
Sponsor: University of California, San Francisco
Summary
The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy. In this 2-year study, the investigators will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2023-03-13
Completion Date
2027-05-31
Last Updated
2025-04-24
Healthy Volunteers
Yes
Conditions
Interventions
Lemborexant
Lemborexant tablet administered orally once daily
Placebo
Placebo to match Lemborexant tablet administered orally once daily
Locations (1)
University of California San Francisco
San Francisco, California, United States